(PCYC:Consolidated Issue Listed on NASDAQ Global Select )
David D. Smith Ph.D.
Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee, Pharmacyclics Inc.
|Age||Total Calculated Compensation||This person is connected to 22 board members in 2 different organizations across 2 different industries.|
See Board Relationships
Dr. David D. Smith, Ph.D. serves as a Principal Research Scientist for the Research and Development Division at Oncotech, Inc. Dr. Smith is responsible for investigating mechanisms of chemotherapeutic resistance. He serves as a Senior Biostatistician at City of Hope, where he has designed and analyzed over 50 solid tumor and hematology protocols at all levels of development, from pre-clinical and genomic studies to Phase II/III trials. Dr. Smith was instrumental in City ...
999 East Arques AvenuePhone: 408-774-0330
Sunnyvale, California 94085
Board Members Memberships*
Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
Texas A&M University
University of California-Los Angeles
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|John C. Martin Ph.D.||Chairman and Chief Executive Officer|
Gilead Sciences Inc.
|George A. Scangos Ph.D.||Chief Executive Officer and Director|
Biogen Idec Inc.
|Robert J. Hugin MBA||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|Andrew Philip Witty||Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee|
|Jan G. J. van de Winkel Ph.D.||Co-Founder, Chief Executive Officer and President|
|kr10.7M||Compensation as of Fiscal Year 2013.|